In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

NIH study finds low-intensity therapy for Burkitt lymphoma is highly effective
NCI Press Release
(Posted: 11/13/2013) - Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates—upwards of 90 percent—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding. Burkitt lymphoma is the most aggressive type of lymphoma, which is a cancer that begins in cells of the immune system.

Young breast cancer patients with poorer financial status may experience delays in seeking care
NCI Cancer Center News
(Posted: 11/12/2013) - Researchers who sought to determine why breast cancers are more deadly in young women found that only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, but delays in seeking care are more common in women with fewer financial resources. Findings of the study, conducted at the Dana-Farber Cancer Institute in Boston, are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

Common genetic pathway could be conduit to pediatric tumor treatment
NCI Cancer Center News
- Investigators at Johns Hopkins and its Kimmel Cancer Center have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers. In laboratory studies, researchers found that the pathway, called mammalian target of rapamycin (mTOR), was highly active in pediatric low-grade gliomas, and that mTOR activity could be blocked using an experimental drug, leading to decreased growth of these tumors.

HPV can damage genes and chromosomes directly
NCI Cancer Center News
- The virus that causes cervical, head and neck, anal and other cancers can damage chromosomes and genes where it inserts its DNA into human DNA, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Published in the journal Genome Research, this laboratory study used whole-genome sequencing to investigate the relationship between the HPV and host genomes in human cancers.

Microbes in the gut help determine risk of tumors
NCI Cancer Center News
- Transferring the gut microbes from a mouse with colon tumors to germ-free mice makes those mice prone to getting tumors as well, according to the results of a study from the University of Michigan (home of the University of Michigan Comprehensive Cancer Center) published in mBio®, the online open-access journal of the American Society for Microbiology. The work has implications for human health because it indicates the risk of colorectal cancer may well have a microbial component.

Mutations linked to breast cancer treatment resistance
NCI Cancer Center News
(Posted: 11/05/2013) - Researchers at the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain one reason why patients often become resistant to this therapy.

Imaging studies may predict tumor response to anti-angiogenic drugs
NCI Cancer Cancer News
(Posted: 11/05/2013) - Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, Massachusetts General Hospital (a component of the Dana-Farber Cancer Institute) researchers report, those for whom treatment with the anti-angiogenic drug cediranib rapidly "normalized" abnormal blood vessels around their tumors and increased blood flow within tumors survived significantly longer than did patients in whom cediranib did not increase blood flow. The report appears in PNAS Early Edition.

Fewer doses of HPV vaccine result in immune response similar to three-dose regimen
NCI News Note
(Posted: 11/04/2013) - NCI scientists report that two doses of a human papillomavirus (HPV) vaccine, trademarked as Cervarix, resulted in similar serum antibody levels against two of the most carcinogenic types of HPV (16 and 18), compared to a standard three dose regimen.

Study uncovers secrets behind the process of some cancers
NCI Cancer Center News
(Posted: 10/29/2013) - Researchers at Fox Chase Cancer Center have discovered new clues about how some genes are turned on and off inside a cell—a process that, when it goes awry, can lead to cancer. The new findings appear online in the October 24, 2013 edition of the journal Cell Reports. The researchers worked to uncover details about how a single protein is able to physically "silence" gene clusters. If certain “tumor suppressor genes” get inadvertently caught up in such silencing, they say, this may cause cells to divide uncontrollably and lead to cancer.

Study finds new genetic error in some lung cancers
NCI Cancer Center News
(Posted: 10/29/2013) - A fine-grained scan of DNA in lung cancer cells has revealed a gene fusion – a forced merger of two normally separate genes – that spurs the cells to divide rapidly, scientists at Dana-Farber Cancer Institute and the University of Colorado Cancer Center report in a new paper in the journal Nature Medicine. Treating the cells with a compound that blocks a protein encoded by one of those genes – NTRK1 – caused the cells to die.

< Previous  9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29  Next >